Neovia Oncology

Name

Neovia Oncology

Legal name

Neovia Oncology LLC

Website

https://neoviaoncology.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Oncology drug development
• Drug-drug conjugates
• Cancer therapeutics
• Topoisomerase inhibitors
• Antibody-drug conjugates

Headquarters

HQ city

Bellevue

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company developing novel oncology therapeutics. Revenue will be generated through eventual drug commercialization and/or licensing partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Neovia Oncology is a clinical-stage biopharmaceutical company developing NEV-801, a novel investigational drug-drug conjugate (DDC) that combines analogs related to irinotecan and etoposide in a plasma-stable architecture engineered for controlled release in tumor microenvironments. The compound is designed to act as a non-poisonous agent against Topo I and Topo II, targeting heavily pretreated patients with late-stage solid tumors who have failed standard chemotherapy, immunotherapy, and radiation treatments.

Product overview

Neovia Oncology is a pharmaceutical company pioneering a novel class of investigational cancer therapeutics through its differentiated DDC (drug-drug conjugate) platform. The core product is NEV-801, a novel dual-mechanism conjugate combining irinotecan and etoposide analogs designed for controlled tumor delivery. The company is also exploring broader platform applications for NEV-801 in next-generation oncology, including antibody-drug conjugate (ADC) strategies. The company is pursuing strategic partnerships for companion diagnostics, manufacturing, and ADC developments.

Differentiator

Problem solved

Functional benefit

Brands

• NEV-801: Novel investigational drug-drug conjugate with dual-mechanism design combining novel analogs related to irinotecan and etoposide, engineered for controlled release in tumor microenvironments.

Products and services

• NEV-801 Investigational novel drug-drug conjugate combining irinotecan and etoposide analogs in a plasma-stable architecture for controlled tumor microenvironment release, designed as a non-poisonous Topo I and Topo II agent for late-line treatment of advanced solid tumors.

Quantifiable outcome

• 62% tumor inhibition (stable disease across cohorts at higher doses)
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Creatv Bio (a division of Creatv MicroTech, Inc.)coreStrategic or Co-development Partner · 2 June 2026Strategic partnership to study multiple drug resistance (MDR) in solid tumors, focusing on Neovia's NEV-801 drug candidate for advanced cancer patients in late lines of therapy. The collaboration will use Creatv's LifeTracDx liquid biopsy blood test to generate translational and biomarker data for patient stratification and treatment response monitoring. Beyond systemic therapy development, Neovia is also exploring broader platform applications for NEV-801 in next-generation oncology, including antibody-drug conjugate strategies.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Mersana Therapeutics: Clinical-stage oncology biotech developing novel antibody-drug conjugates with proprietary payload and linker platforms, including topoisomerase-payload ADCs. Highly comparable as a small-cap, clinical-stage ADC innovator pursuing differentiated payload chemistry — closely aligned with Neovia's NEV-801 DDC/ADC strategy.
• CytomX Therapeutics: Clinical-stage oncology company developing Probody-enabled therapeutics and ADC conjugates designed for tumor-selective activation. Comparable as a platform-based oncology drug developer focused on improving the therapeutic index of cytotoxic payloads, mirroring Neovia's tumor-microenvironment-activated approach.

Emerging players

• ProfoundBio: Clinical-stage ADC developer with a proprietary payload and linker platform targeting topoisomerase and other mechanisms. Comparable as an emerging ADC innovator focused on next-generation payload chemistry for solid tumors, similar to Neovia's DDC-to-ADC platform thesis.
• Pyxis Oncology: Clinical-stage oncology biotech developing novel ADCs and immunotherapies. Comparable as a small-cap ADC platform developer pursuing differentiated payload approaches for solid tumors, with similar strategic positioning to Neovia.
• Bolt Biotherapeutics: Clinical-stage oncology company developing ISAC (immune-stimulating antibody conjugate) platforms. Comparable as an early-stage company developing novel antibody-conjugate oncology therapeutics with proprietary payload/linker technology, aligned with Neovia's drug-conjugate innovation strategy.
• Tubulis: Clinical-stage ADC developer with proprietary payload-linker chemistry platforms. Comparable as an emerging ADC innovator focused on differentiated payload chemistry for solid tumor indications.

Broad incumbents

• Daiichi Sankyo: Japanese pharmaceutical major and ADC pioneer (Enhertu, Datroway) leveraging topoisomerase-payload ADCs across multiple solid tumor indications. Comparable as the dominant broad incumbent in the topoisomerase-ADC space that Neovia would need to differentiate against.
• AstraZeneca: Global biopharmaceutical company with a leading ADC franchise (Enhertu via partnership with Daiichi Sankyo, Trodelvy). Comparable as a broad incumbent developing topoisomerase-payload ADCs and competing for the same oncology combination and indication space.
• Pfizer: Global biopharmaceutical company with multiple oncology ADC assets (Padcev, Tivdak) and significant R&D investment in next-generation antibody conjugates. Comparable as a broad incumbent pursuing topoisomerase and novel payload ADCs across solid tumor indications.
• ImmunoGen (AbbVie): ADC pioneer (Elahere for platinum-resistant ovarian cancer) now part of AbbVie. Comparable as an established ADC innovator whose late-line solid tumor focus and topoisomerase-payload experience directly overlap with Neovia's positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neovia Oncology